interleukin-4 receptor subunit α

Dupilumab (REGN-668) belongs to antibody inhibitors and is an IL-4Rα-targeted inhibitor that exerts anti-inflammatory effects by blocking IL-4 and IL-13 signaling. This compound possesses high selectivity and is mainly used for the treatment of moderate-to-severe atopic dermatitis.

Manfidokimab (AK120) is a human monoclonal antibody of the IgG4 subclass that specifically targets the interleukin-4 receptor alpha subunit (IL-4Rα). by binding to this shared subunit, Manfidokimab simultaneously blocks the downstream signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), and Manfidokimab can be used in studies about moderate to severe atopic dermatitis.